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Abstract
Background: Alternating Hemiplegia of Childhood (AHC) is a severe disorder. Several drugs have been administered as prophy-
laxis for paroxysmal attacks, however, no therapy is completely effective.
Methods: Our aim is to review the pharmacological data related to the prophylactic and acute treatment of a cohort of 30
patients (16 M, 14 F, age range 5–42 years) and to correlate them with the clinical and genetic data collected through the Italian
Biobank and Clinical Registry for AHC.
Results: Flunarizine was the most commonly used long-term treatment in the cohort; it reduced duration and frequency of
attacks in 50% of patients and decreased intensity in 32.1%. In younger patients, flunarizine seemed significantly more effective
in reducing intensity. We found no correlation between the effectiveness of flunarizine and genotype, or between developmental out-
come and duration of treatment. In particular, 3 of our patients affected by E815K mutation presented rapid neurological deteri-
oration despite ongoing treatment. Among the other administered prophylactic therapies, few proved to be effective
(benzodiazepines, niaprazine, acetazolamide, melatonin, olanzapine, ketogenic diet). No clear rationale exists regarding their use,
but these therapies may work by reducing the triggering factors.
Conclusions: The presented data are retrospective, but they are aimed at filling a gap given the rarity of the disease and the lack of
randomized and controlled studies. Besides their usefulness in clarifying the pathophysiology of the disease, prospective studies
involving larger cohorts of ATP1A3 mutated AHC patients are needed to provide a rationale for testing other molecules.
 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
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Alternating Hemiplegia of Childhood (AHC) is a
rare, predominantly sporadic disorder with an incidence
of one affected individual in one million births (OMIM
104290, 614820), and it is characterized by the early
onset (within 18 months of age) of a combination of
paroxysmal attacks and permanent neurological
features.
The etiology of the syndrome was unknown until
2012, when heterozygous de novo mutations in the
ATP1A3 gene that codes for the a3 isoform of the Na
+/K+ ATPase were detected in more than 75% of
AHC patients [1].
Since phenotype variability of AHC is extensive, drug
therapy is often difficult and challenging. The main
objectives of drug therapy are to prevent paroxysmal
attacks by means of prophylactic therapy, and to stop
paroxysms by inducing sleep which often blocks a crisis.
Other paroxysmal manifestations requiring treatment
include epilepsy (which may be associated in approxi-
mately 50% of patients) and migraine. Several combina-
tions of movement disorders (such as chorea, myoclonus
and dystonia) with various degrees of severity, and psy-
chiatric comorbidities vary from patient to patient and
represent other targets for treatment.
Several drugs have been used since AHC was first
described, mainly to control the paroxysmal attacks that
represent the most disturbing symptoms. Due to the rar-
ity of this disease, prospective, randomized and con-
trolled studies are lacking. Currently, only flunarizine,
a calcium entry blocker, has been shown to reduce the
severity and/or duration of AHC attacks [2,3].
The aim of this study was to review the pharmacolog-
ical data regarding the prophylactic and acute treatment
of an Italian cohort of patients and to correlate treat-
ment response to clinical, demographic and genetic data.
2. Subjects
The clinical, demographic, genetic and pharmacolog-
ical data of 30 AHC patients (16 males - 53.3%, 14
females - 46.7%) ranging in age from 5 to 42 years
(20.9 ± 10 years) were collected from the I.B.AHC (the
Italian Biobank and Clinical Registry for AHC: www.
ibahc.org). Data were collected by the patient’s referring
paediatric neurologist and subsequently validated by the
I.B.AHC data managers (MG, EDG and MS). Diag-
noses were established by consensus among the mem-
bers of the Scientific Committee of the Italian Patient
Association (A.I.S.EA) on the basis of the 7 specific
diagnostic clinical criteria [4] and by analysing video
recordings during and between paroxysmal attacks. All
patients (or parents acting on their behalf) gave
informed consent to participate in the study and eachPlease cite this article in press as: Pisciotta L et al. Alternating Hemipleg
Brain Dev (2017), http://dx.doi.org/10.1016/j.braindev.2017.02.001patient underwent molecular analysis of the ATP1A3
gene.
3. Methods
The following data were analysed: onset of disease;
age at last follow-up; gender; clinical manifestations
(epilepsy, migraine, cognitive impairment, dystonia,
walking disability, language impairment); genotype
(presence and type of ATP1A3 mutation); frequency,
severity and duration of each type of paroxysmal attack
(tonic/dystonic/plegic) before and after administration
of every prophylactic and/or symptomatic therapy;
reported side effects.
Drugs were classified as follows: sleep-inducing treat-
ments, benzodiazepines, anti-epileptic drugs (AEDs),
drugs for spasticity and movement disorders, antimi-
graine, antidepressant, anti-psychotic, anti-inflammatory
(including non steroidal anti inflammatory drugs), parac-
etamol, corticosteroids, hormonal therapies, vitamins
and supplements, homeopathy and other therapies (keto-
genic diet (KD), vagal stimulation, relaxation techniques).
A favourable response was empirically defined as a clini-
cally significant reduction in terms of frequency, duration
or intensity of the spells according to the referring
neurologist, evident and sufficient to warrant continuation
of the treatment.
Treatment with flunarizine was specifically analysed.
Using the I.B.AHC database, as well as the patients’
charts and the interviews with family members and par-
ents, we rated intensity, duration and frequency of the
attacks before and after treatment in order to achieve
data standardization. A numerical scale ranging from
1 to 10 (1 = low intensity, 10 = high intensity) was used
to assess the intensity of the attacks, while duration was
measured in hours, and frequency in number of episodes
per week. The percentage of positive or negative modifi-
cations was calculated for each item in order to measure
the effects of flunarizine, while to better define the num-
ber of patients in whom there was no or only minimum
change in the frequency, intensity, and duration of
paroxysmal attacks, we decided to categorize the
response rate, considering a minimum cut-off of 30%
as a significant decrease.
The Flunarizine Index (FI), defined as the duration of
the treatment with flunarizine divided by the patient’s
age [2], was also calculated.
The hypothesis that the cognitive and neurological
outcome of these patients might be correlated with the
duration of flunarizine treatment was investigated by
comparing the FI to the cognitive profile, the presence
and severity of dystonia and any impairment of autono-
mous walking and speech.
The data in our statistical analysis were described as
mean and standard deviation (SD) or median and rangeia of Childhood: Pharmacological treatment of 30 Italian patients.
Table 1
Characteristics of patients with Alternating Hemiplegia of Childhood.
Characteristics of Patients All N (%)
N 30








Gender M/F 16/14 (53.3/46.7)
Epilepsy, yes 12 (40)

















Mild impairment 5 (16.7)
Moderate impairment 8 (26.7)












Negative at genetic investigations 4 (13.3)
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frequencies for categorical variables.
The normality of variables distribution was assessed
using the Kolmogorov–Smirnov test.
Non parametric analysis (Kruskal–Wallis, Mann–
Whitney and Wilcoxon tests) for continuous variables
and the Chi square or Fisher’s exact test for categorical
variables were used to measure differences between
groups. A p-value less than 0.05 was considered statisti-
cally significant; all p-values were based on two-tailed
tests. Statistical analysis was performed using SPSS
for Windows (SPSS Inc., Chicago, Illinois USA).
4. Results
The clinical features of our series of 30 patients are
shown in Table 1.
In our cohort flunarizine was used in 29/30 patients
for a mean period of 12.8 years (±9.8 SD), ranging from
12 months to 28 years, median value 10 years. Data
about daily dosage of flunarizine were available in
23/29 patients: mean value 8.2 mg/day ±2.9 SD, median
value 10 mg/day (range 3.25–15). Side effects [worsening
of dystonia (n = 2), sedation (n = 1), rash (n = 1), gingi-
val hypertrophy (n = 1), weight gain (n = 1) and disequi-
librium (n = 1)] per se were mild and transient, but
together with the lack of efficacy, they led to permanent
or temporary discontinuation of the therapy in 13/29
patients. Four out of 13 patients (30.8%) permanently
discontinued the treatment, while 1/13 (7.7%) temporar-
ily discontinued flunarizine for 6–7 months due to side
effects resulting from dose elevation. Eight out of 13
(61.5%) later resumed therapy due to the worsening of
symptoms after discontinuation. None of the patients
discontinued flunarizine solely due to the side effects,
but also because of a lack of efficacy. In our statistical
analysis of the efficacy of flunarizine we considered
28/29 patients because one patient (aged 23) had been
on the drug since early in life, thus making it difficult
to assess the effectiveness of the treatment on attacks.
In the 28 patients who were administered flunarizine, a
significant improvement in terms of duration, intensity
and frequency of attacks (p = 0.02, p = 0.005 and
p = 0.0001, respectively) was observed between pre- ver-
sus post-treatment (Table 2). A greater than 30% reduc-
tion in the duration of attacks was reported in 14/28
(50%), and lower intensity was observed in 9/28
(32.1%). A reduction in frequency greater than 30%
was reported in 14/28 patients (50%), while in five
patients flunarizine was not effective on any of the
parameters. Six out of 28 patients (21.4%) had a >30%
decrease in all parameters; 2/28 (7.1%) had a >50%
decrease in all parameters; none had a greater than
75% response in all parameters.
Comparing the age of the patients to the effectiveness
of flunarizine (in terms of reduction of frequency,Please cite this article in press as: Pisciotta L et al. Alternating Hemipleg
Brain Dev (2017), http://dx.doi.org/10.1016/j.braindev.2017.02.001intensity and duration of paroxysmal attacks) revealed
no significant correlations except that in younger
patients flunarizine was significantly more effective in
reducing the intensity of attacks (percentage of reduc-
tion 15.8 ± 8.6 vs 24.4 ± 8.6, p = 0.01).
Comparing the FI to long-term clinical outcome, no
statistically significant correlations were found (absent
or mild cognitive impairment 0.65 ± 0.32 vs moderate
or severe 0.58 ± 0.36, p = 0.62; absent or mild dystonia
0.60 ± 0.35 vs moderate or severe dystonia 0.62 ± 0.36,
p = 0.98; autonomous walking 0.64 ± 0.33 vs not auton-
omous or impossible 0.46 ± 0.38, p = 0.21; mild or no
language impairment 0.65 ± 0.33 vs moderate or severe
language impairment 0.55 ± 0.37, p = 0.35) (Table 3).
Moreover, no statistically significant correlation
between the developmental outcome and flunarizineia of Childhood: Pharmacological treatment of 30 Italian patients.
Table 2
Effects of Flunarizine on duration, intensity and frequency of paroxysmal attacks in Alternating Hemiplegia of Childhood.
Effect of Flunarizine Pre-Flunarizine Post-Flunarizine P value
N 28 28
Duration of attacks (hours) mean ± SD 82.6 ± 140 38.8 ± 57 0.002
median (range) 48 (0.3; 730) 9 (0.03; 240)
Intensity of attacks (*) mean ± SD 7.8 ± 1.9 6.2 ± 2.2 0.005
median (range) 8 (2; 10) 6 (1; 10)
Frequency of attacks (per week) mean ± SD 5.3 ± 12.9 1.8 ± 3 0.0001
median (range) 1 (0.12; 70) 0.75 (0.06; 14)
* Numerical scale ranging from 1 to 10 (1 = low intensity, 10 = high intensity).
4 L. Pisciotta et al. / Brain & Development xxx (2017) xxx–xxxefficacy on the duration, intensity and frequency of
attacks was found (Supplemental Table).
In order to evaluate the correlation between the effec-
tiveness of flunarizine and the genotype, we considered
the two most frequent mutations (D801N, E815K) andTable 3














1 9 E815K 0.50 2 0
2 16 neg 0.73 0 1
3 13 C333F 0.83 2 1
4 17 neg 0.04 2 2
5 24 D801N 0.09 2 2
6 23 D801N 0.95 // //
7 9 G947R 0.75 0 0
8 17 G947R 0.86 2 2
9 22 919delV 0.81 0 3
10 14 I274N 0.77 0 0
11 29 D801N 0.94 0 1
12 37 D801N 0.78 0 0
13 14 E815K 0.99 1 2
14 43 D801N 0 // //
15 31 neg 0.90 2 2
16 23 E815K 0.05 0 0
17 35 E815K 0.70 2 2
18 35 E815K 0.70 2 2
19 6 D801N 0.50 0 1
20 39 D801N 0.71 0 2
21 29 neg 0.11 2 2
22 15 M806R 0.86 3 1
23 18 E815K 0.29 0 0
24 26 D801N 0.92 0 2
25 20 D801N 0.93 2 2
26 13 E815K 0.95 0 0
27 13 A955D 0.08 2 2
28 23 L888P 0.91 0 0
29 34 D801N 0.06 2 2
30 9 A338P 0.63 0 0
Genotype: neg = patient resulted negative at molecular analysis of the ATP
FI (Flunarizine Index) = duration of Flunarizine treatment/patient’s age;
Effect of Flunarizine on frequency/intensity/duration of attacks: 0 = re
// = patient that was never administered Flunarizine or unassessable data;
Cognitive Impairment: 0 = absent, 1 = mild, 2 = moderate, 3 = severe;
Dystonia: 0 = absent, 1 = mild, 2 = moderate, 3 = severe;
Walking: 0 = autonomous; 1 = not autonomous, 2 = impossible;
Language: 0 = normal, 1 = mild impairment, 2 = moderate impairment, 3 =
Please cite this article in press as: Pisciotta L et al. Alternating Hemipleg
Brain Dev (2017), http://dx.doi.org/10.1016/j.braindev.2017.02.001grouped all other mutations. Then we divided the
patients into four groups: patients with D801N (8 cases);
patients with E815K (7 cases); patients with other
mutations (9 cases); patients with no mutations









0 3 0 2 3
0 2 3 1 2
2 1 1 0 1
2 2 2 0 2
1 1 1 0 1
// 1 1 0 0
0 1 1 0 0
2 1 1 0 0
0 2 2 0 2
0 1 1 0 0
0 2 0 0 0
2 2 1 0 1
2 2 2 0 2
// 2 0 0 0
0 1 1 0 0
0 3 2 1 2
0 3 3 2 3
0 3 3 2 3
2 0 0 0 0
1 2 1 0 0
0 2 1 0 0
1 1 1 1 2
0 3 3 2 3
0 1 0 0 0
2 2 1 0 1
1 3 2 2 2
2 3 1 2 3
2 3 2 1 3
2 1 1 0 1
0 2 0 0 2
1A3 gene;
duction > 30%, 1 = reduction < 30%, 2 = no effect, 3 = worsening,
severe impairment.
ia of Childhood: Pharmacological treatment of 30 Italian patients.
Table 4
Effect of flunarizine on genotype in Alternating Hemiplegia of Childhood.




























N (%) N (%) N (%) N (%) N (%)
Frequency
Reduction 18 (64.3) 4 (50) 6 (85.7) 5 (55.6) 3 (75) 0.28 1 0.57 0.31 1 1
No effect 10 (35.7) 4 (50) 1 (14.3) 4 (44.4) 1 (25)
Intensity
Reduction 14 (50) 3 (37.5) 4 (57.1) 6 (66.7) 1 (25) 0.62 0.35 1 1 0.54 0.27
No effect 14 (50) 5 (62.5) 3 (42.9) 3 (33.3) 3 (75)
Duration
Reduction 15 (53.6) 5 (62.5) 4 (57.1) 5 (55.6) 1 (25) 1 1 0.54 1 0.54 0.56
No effect 13 (46.4) 3 (37.5) 3 (42.9) 4 (44.4) 3 (75)
Fisher’s exact test.
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in terms of reducing the frequency, duration and inten-
sity of the attacks did not yield any statistically specific
or significant correlations when comparing the four
groups (Table 4). The clinical data of all patients was
compared among these mutation groups and statistically
significant differences were observed in group 2, in rela-
tion to other groups (Table 5). Clinical outcome was
definitely better in patients with the D801N mutation
(dystonia, cognitive impairment, walking and language),
and in particular, as compared to patients with the
E815K mutation. At the time of evaluation, none of
the 7 patients with the E815K mutation had ever discon-
tinued flunarizine; despite ongoing treatment, three of
them experienced psychomotor regression. Two patients
(twins, patients n. 17 and 18) became bedridden and lost
the ability to speak, apparently because of statusTable 5
















N (%) N (%) N (%) N
Cognitive impairment
Absent/ mild 4 (50) – 5 (55.6) 1 (
Moderate/ severe 4 (50) 7 (100) 4 (44.4) 3 (
Dystonia
Absent/ mild 8 (100) 1 (14.3) 7 (77.8) 2 (
Moderate/ severe – 6 (85.7) 2 (22.2) 2 (
Walking
Autonomous 8 (100) 2 (28.6) 8 (88.9) 4 (
Not autonomous/ impossible – 5 (71.4) 1 (11.1) –
Language impairment
Absent/ mild 8 (100) – 4 (44.4) 2 (
Moderate/ severe – 7 (100) 5 (55.6) 2 (
Bold = statistically significant – Fisher’s exact test.
Please cite this article in press as: Pisciotta L et al. Alternating Hemipleg
Brain Dev (2017), http://dx.doi.org/10.1016/j.braindev.2017.02.001epilepticus; patient n. 26 had a behavioural regression
due to ongoing severe dystonic episodes, and died a
few months later of a heart attack.
In our cohort of 30 patients, 24 (80%) had received
AEDs during their life, often in polytherapy. The most
often used AEDs in our cohort were: valproic acid
(16/24), phenobarbital (14/24), carbamazepine (13/24),
topiramate (10/24), clobazam (8/24), phenytoin (6/24),
lamotrigine (3/24), ethosuximide (2/24), vigabatrin
(1/24), felbamate (1/24) and levetiracetam (1/24). None
of these AEDs was reported to be effective on non-
epileptic paroxysmal attacks.
Some other prophylactic drugs proved to be effective:
benzodiazepines (7/12), niaprazine (4/7), acetazolamide
(3/6), melatonin (2/5), olanzapine (2/2), 5-
hydroxytryptophan (1/2), amitriptyline and mirtazapine

















25) 0.07 1 0.57 0.03 0.36 0.56
75)
50) 0.001 0.47 0.09 0.04 0.49 0.53
50)
100) 0.007 1 – 0.03 0.06 1
50) 0.0001 0.03 0.09 0.09 0.11 1
50)
ia of Childhood: Pharmacological treatment of 30 Italian patients.
Graph 1. Drugs other than flunarizine used as prophylaxis of paroxysmal attacks in Alternating Hemiplegia of Childhood.
6 L. Pisciotta et al. / Brain & Development xxx (2017) xxx–xxxhad to be discontinued due to side effects. Many drugs
were administered without efficacy on paroxysmal
attacks including levodopa-carbidopa (1/30), aman-
tadine (1/30), baclofen (2/30), and anti-migraine thera-
pies (nimodipine, pizotifene, clonidine, each in 1/30).
Risperidone, an anti-psychotic drug, was administered
to 2/30 (no efficacy in 2/2), and haloperidol was given
to 2/30 (clinical worsening in both patients), while
among antidepressants, sertraline was given to 1/30
(no effects on attacks) and paroxetine to 1/30 (with side
effects) (Graph 1).
Regarding the acute treatment of attacks (Graph 2),
benzodiazepines proved helpful in 25/27, niaprazine in
5/5, chloral hydrate in 2/2. The most often used
among benzodiazepines was diazepam (25/30) which
was effective in 19/25 (76%) and showed side effects
in 6/25 (24%) [intense sedation (n = 2), paradoxicalGraph 2. Drugs used in the treatment of acute paroxysmal attacks in
Alternating Hemiplegia of Childhood.
Please cite this article in press as: Pisciotta L et al. Alternating Hemipleg
Brain Dev (2017), http://dx.doi.org/10.1016/j.braindev.2017.02.001effect (n = 2), hypoventilation (n = 2)]. Among other
drugs, midazolam was used in 5/30 (and was effective
in 5/5 patients), clonazepam in 3/30 (effective in 1/3),
alprazolam in 3/30 (positive effects in 2/3), lormetaze-
pam in 1/30 and lorazepam in 1/30 (effective in both
patients). Delorazepam was given to 2/30 patients,
though without any effect.
5. Discussion
No drugs are currently available to cure AHC. Pre-
sently, drugs are being used to reduce paroxysmal
attacks, to treat epilepsy when present, and to minimize
chronic neurological manifestations. Several drugs have
been used in the last years to treat paroxysmal symp-
toms, but flunarizine represents the current drug of
choice [4]. Flunarizine is a non selective blocker of
voltage-dependent calcium channels and it has recently
been demonstrated that it also blocks sodium currents,
thus preventing high frequency firing of cortical neurons
and decreasing cortical hyperexcitability [5]. Several case
reports and case series reported its efficacy in reducing
the number of attacks and their duration [2–4] but
prospective, randomized, controlled trials are still lack-
ing because of the rarity of this disorder.
In our series, flunarizine proved to be efficacious in
23/28 (82%) patients. Side effects were mild and tolera-
ble; none of the patients discontinued the drug solely
because of adverse effects but mainly due to a lack of
efficacy.
We observed that in younger patients flunarizine was
significantly more efficacious in reducing intensity. It is
possible that the natural history of AHC, which overia of Childhood: Pharmacological treatment of 30 Italian patients.
L. Pisciotta et al. / Brain & Development xxx (2017) xxx–xxx 7the years has shown a noteworthy reduction in fre-
quency and intensity of paroxysmal attacks [2], may
have biased the true efficacy of flunarizine in the adult
patients of our cohort.
Despite positive response in many AHC patients, the
role of flunarizine in changing the course of the disease,
and especially the cognitive outcome, is still uncertain.
The Flunarizine Index, defined as the duration of the
treatment with flunarizine divided by the patient’s age,
was meant to investigate a possible positive or negative
correlation between the duration of treatment and the
developmental outcome. This could be considered an
important index since most patients end up receiving
the medication for years [2]. Some authors raised the
possibility that flunarizine could have a long-term effect
on the motor and intellectual development in respond-
ing patients [3], in particular, the same authors recently
demonstrated that 8 patients (5 of whom were affected
by the E815K mutation) with severe motor deterioration
had not been administered flunarizine during the period
of deterioration [6]. Our experience does not support
this finding. First of all, in accordance with Mikati
and co-authors [2], we did not observe a correlation
between the developmental outcome and the duration
of the treatment with flunarizine, or its efficacy on the
duration, intensity and frequency of attacks. Moreover,
3 of the patients in our cohort with the E815K mutation
(patients n. 17, 18 and 26) presented rapid motor deteri-
oration, a sudden worsening of dystonia and loss of lan-
guage despite ongoing treatment. As far as psychomotor
deterioration is concerned, we suspect that a genetic fac-
tor rather than the treatment with flunarizine could be
primarily involved, since it is now known that patients
with E815K have one of the most severe phenotypes
[7]. Interestingly, this kind of clinical course showing
severe deterioration and no recovery is typical of Rapid
Onset Dystonia Parkinsonism, another allelic disorder
caused by the ATP1A3 mutation [6]. On the other hand,
it seems that long term motor outcome of our ATP1A3
genetically confirmed patients is better than in previous
studies: 17/26 patients (65.4%) could autonomously
walk versus 14/33–42.4% of the Japanese cohort [6];
6/26 patients (23.1%) did not present dystonia versus
6/45–13.3% of the Chinese cohort [8]. In both cohorts,
proportion of patients continuously treated with flunar-
izine was lower [6,8]. These data, together with the good
clinical course seen in at least 30% of our patients, may
prompt a long-term usage of flunarizine in individual
clinical situations. Further larger studies are needed to
investigate a possible protective role of therapy with
flunarizine.
Genotype may also affect response to treatment with
flunarizine, but we were unable to find any correlation
between the efficacy of flunarizine and genotype. To
date, no studies but the present one have specifically
analysed this kind of correlation, therefore we canPlease cite this article in press as: Pisciotta L et al. Alternating Hemipleg
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patients, regardless of the type of mutation, however
this hypothesis needs to be further investigated in future
studies.
Considering the high frequency of epilepsy in this dis-
ease (50% according to the literature) and the difficulty
in making a differential diagnosis, patients often try
many different AEDs before starting flunarizine and
they continue both therapies even after receiving a
definitive diagnosis of AHC. This is why it was difficult
for us to understand the real efficacy of AEDs on non-
epileptic attacks.
Interestingly, in our cohort other prophylactic drugs
such as benzodiazepines in 58%, niaprazine in 57%,
acetazolamide in 50%, melatonin in 40% also proved
to be effective, as did some other therapies with olanza-
pine, 5-hydroxytryptophan, amitriptyline and mirtazap-
ine, which had been administered to a few patients. No
clear rationale exists towards the prescription of any of
these drugs. However, we do know that trigger factors
such as stress, tiredness or strong emotions can induce
or worsen paroxysmal episodes. We hypothesize that
by improving the wake-sleep cycle or reducing anxiety
and depression in our patients some of these
drugs may have had secondary effects on paroxysmal
episodes.
Interestingly, some authors reported that a KD had a
beneficial effect on paroxysmal attacks in some AHC
patients [9,10]. One of our patients (patient n. 27) had
an excellent response with a traditional KD; however,
KDs are very difficult to manage and after one year
the diet was discontinued due to side effects (vomiting,
increase in cholesterol and transaminases, weight gain).
Taken together, all these observations suggest that a KD
might represent a promising therapeutic option in AHC.
Our study underlines that benzodiazepines repre-
sented the drug of choice for the acute treatment of
hemiplegic attacks in our cohort, leading to resolution
or reduction in severity. Other acute treatment options
could be niaprazine and chloral hydrate, which however,
are not available for use outside the hospital in Italy.
In general, it is very important to recognize and pre-
vent the trigger factors of hemiplegic attacks, such as
strong emotions, physical effort, sudden temperature
changes and bathing. Many families report that in most
cases medical intervention is not needed; merely placing
the patient in a quiet environment, sheltered from light
and noise, may lead to relaxation and sleep [11].
The main limitation of our study is its retrospective
nature. We know that this type of study is subject to
some biases. However, given the lack of randomized
and controlled studies, and most of all, of a reliable
rationale for choosing appropriate drugs, we do believe
that our observations might be beneficial to clinicians
who need to choose the most suitable treatment strate-
gies to deal with this rare disorder.ia of Childhood: Pharmacological treatment of 30 Italian patients.
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In our Italian cohort, flunarizine was the most com-
monly used drug. A significant improvement in terms
of reducing duration, intensity and frequency of attacks
was observed between pre- versus post-treatment. Geno-
type does not seem to influence the response to flunar-
izine; however, larger controlled studies are warranted.
Several other drugs might be used to improve patients’
health as well as to reduce the intensity and frequency
of paroxysmal attacks. Further studies on the response
to treatment in a cohort of AHC patients affected by
the ATP1A3 mutation, together with the recent discov-
ery of the biological basis of the disorder, will contribute
to clarifying the pathophysiology and providing the
rationale for the use of newer and more efficacious
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